JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; currently in preclinical development; Phase 1 clinical trial expected to commence in the first half of 2027 Approximately $336 million of cash, cash equivalents, and investments as of December 31 st , 2025 expected to provide runway into the first half of 2028 Company to present at the 44 th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 a.m.
